Q86.1
Fetal hydantoin syndrome
Clinical Classification Guidelines
Inclusion Terms
- Meadow's syndrome
Medical Intelligence & Overview
Fetal Hydantoin Syndrome (FHS) is a condition that affects babies born to mothers who took hydantoin medications during pregnancy. Hydantoin drugs are used to treat seizures, but their use during pregnancy can sometimes lead to specific birth defects and developmental issues. FHS is sometimes referred to as Meadow's syndrome. Recognizing this syndrome helps in understanding its potential effects and the importance of medical management during pregnancy.
Causes & Symptoms
Clinical Causes: Use of hydantoin anticonvulsant medications (such as phenytoin) during pregnancy Inconsistent prenatal care Lack of awareness about medication risks during pregnancy Maternal health issues that necessitate anticonvulsant therapy
Key Symptoms: Characteristic facial features, including broad nasal bridge, small or midline facial clefts, and maxillary hypoplasia Hypoplastic nails and distal phalanges Digital and limb abnormalities such as hypoplastic fingernails Growth deficiencies or microcephaly (small head size) Cleft lip or palate Congenital heart defects Developmental delays and intellectual disabilities
Diagnostic & Treatment
Diagnosis Path: Diagnosis of Fetal Hydantoin Syndrome is primarily based on clinical features observed after birth, combined with a detailed maternal history of medication use during pregnancy. Genetic testing and imaging studies can assist in identifying associated anomalies. Healthcare providers also consider the timing and dosage of hydantoin exposure when assessing the likelihood of FHS.
Treatment Protocols: There is no specific treatment to reverse the physical features associated with FHS. Management involves a multidisciplinary approach focusing on addressing individual health issues, such as surgical correction of cleft lip or palate, therapy for developmental delays, and treatment for congenital heart defects. Prevention through careful medication management and counseling during pregnancy is essential to reduce the risk of FHS.
Clinical Advice & FAQs
Billing Guidance
Is Q86.1 a billable ICD-10 code?
Yes, Q86.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Q86.1?
Clinical documentation must specify the nature of Fetal hydantoin syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference